GSK taps Sino Biopharm unit to speed bepirovirsen launch in China

GSK has signed an exclusive strategic collaboration with Chia Tai Tianqing Pharmaceutical Group, a Sino Biopharmaceutical subsidiary, to speed the mainland China launch of bepirovirsen, its investigational chronic hepatitis B treatment, according to reports published May 11, 2026. Under the arrangement, GSK will remain the marketing authorization holder and keep responsibility for regulatory affairs, quality control, pharmacovigilance, and global medical strategy, while CTTQ will support commercialization in mainland China. The move comes just weeks after China’s National Medical Products Administration accepted bepirovirsen for review, and after GSK reported positive phase 3 B-Well 1 and B-Well 2 data and secured U.S. FDA priority review with a PDUFA date of October 26, 2026. (nbd.com.cn)

Why it matters: While this is a human biopharma story rather than an animal health one, it’s still relevant to veterinary professionals tracking how large drugmakers are building launch pathways for complex, specialty medicines in China. The partnership shows a familiar pattern: multinational companies are pairing late-stage or prelaunch assets with local commercial infrastructure to accelerate market access, especially in high-burden disease areas. It also underscores continued momentum behind oligonucleotide medicines, a modality GSK has been investing in more broadly. (gsk.com)

What to watch: The next milestones are China review progress, presentation and publication of the phase 3 data in 2026, and the U.S. FDA decision expected by October 26, 2026. (gsk.com)